GlassScriptPhysician profile
Michael D Gwinn
NPI 1134152002
$876.37
in general payments reported to CMS, 2019-2025
14 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $30.37 · 2021: $30.90 · 2022: $45.65 · 2023: $188 · 2024: $218 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.54 | 2022-2025 | |
| Allergan, INC. | $120.39 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $114.22 | 2024-2025 | Dysport |
| Avanir Pharmaceuticals, INC. | $55.84 | 2019 | |
| Merz Pharmaceuticals, LLC | $47.07 | 2025 | Xeomin |
| Neurelis, INC. | $39.19 | 2024 | Valtoco |
| Abbott Laboratories | $28.92 | 2025 | Eterna |
| Otsuka America Pharmaceutical, INC. | $26.33 | 2023 | Nuedexta |
| Acadia Pharmaceuticals INC | $21.78 | 2024 | Nuplazid |
| Ucb, INC. | $21.09 | 2024 | Briviact |
| Collegium Pharmaceutical, INC. | $21.08 | 2025 | Belbuca |
| Janssen Pharmaceuticals, INC | $15.75 | 2019 | |
| Lilly USA, LLC | $12.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gwinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.